Although we cannot formally confirm it, it seems reasonable to speculate that changing the subcellular localization of HIF-2α and thus their transcriptional activity, could lead to a clinical improvement in RCC tumor patients [60]. Here, EPAS1 is linked to renal cell carcinoma.